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Polianskyi†; Dr Volodymyr Pyrohovskyi; Dr Sergii Shevchuk; Dr 
Grygorii Ursol; Dr Valeriy Vdovychenko; Dr Vira Vyshyvanyuk 
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Curtis Baum; Dr Emanuelle Bellaguarda†; Dr Bonnie Bock†; Dr Tasha 
Boone; Dr Norman Callahan†; Dr Jonathon Chapman†; Dr Stuart Chen†; 
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Ronald Fogel; Dr Juan Frias†; Dr Philip Ginsburg†; Dr Eugene 
Greenberg; Dr David Grunkemeier†; Dr Paul Hellstern; Dr Hans 
Herfarth; Dr Brenda Hoffman; Dr Sara Horst†; Dr Samuel Idarraga; Dr 
Heba Iskandar†; Dr Rajesh Jain†; Dr Erin Jenkins†; Dr Barry Kaufman†; 
Dr Abdul Khaleq†; Dr Ahtaram Khan†; Dr Sunil Khurana; Dr Jason 
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Jennifer Martin†; Dr Matthew McCullough; Dr Alfred McNair†; Dr 
Nilesh Mehta†; Dr Ece Mutlu†; Dr Vijay Narayen†;  Dr Jorge Paoli-
Bruno; Dr Nolan Perez†; Dr Raymond Phillips†; Dr Isaac Raijman; Dr 
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List of Highest Recruiting Sites 
 
Sites with >3% total enrollment 
Investigator name 
City/State or 
Province Country 
Adalimumab 
SC (N = 386), n 
Vedolizumab 
IV (N = 385), n 
Dr Jeffrey Axler Vaughan/Ontario Canada 8 13 
Dr Jaroslaw Kierkus Warszawa Poland 12 10 
Dr Beata Gawdis-
Wojnarska 
Szczecin Poland 7 14 
Note: Only sites with greater than 3% of total enrollment in any treatment group are included. 
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VARSITY Steering Committee  
Bruce E. Sands, MD (Chair), Stefan Schreiber, MD, Laurent Peyrin-Biroulet, MD, PhD, Edward 
V. Loftus Jr., MD. 
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Data Safety Monitoring Board 
Keith Lindor, MD (Chair), Henry Bodenheimer Jr., MD. 
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Progressive Multifocal Leukoencephalopathy (PML) Adjudication Committee  
David B. Clifford, MD (Chair), Eugene O. Major, PhD, Michael H. Lev, MD, Joseph R. Berger, 
MD. 
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Concomitant Corticosteroid Discontinuation/Tapering  
Patients who were receiving oral corticosteroids and had a clinical response at Week 6 as 
assessed by the Investigator began a non-fixed corticosteroid tapering regimen. Patients who did 
not achieve clinical response at Week 6 initiated tapering on a subsequent study visit as soon as a 
clinical response was achieved. For patients who could not tolerate the corticosteroid taper 
without recurrence of clinical symptoms, corticosteroids could be increased up to the baseline 
corticosteroid dose one time before tapering was restarted. In such cases, the tapering regimen 
above was reinitiated within 2 weeks. Patients who consistently could not be tapered were 
withdrawn from the trial.  
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PML Monitoring  
All patients were closely monitored for signs and symptoms of PML prior to administration of 
each dose of trial drug using a PML subjective symptom checklist, which assessed for any recent 
changes in vision, speech, gait, sensation, comprehension, coordination, and personality. Any 
positive response on the PML checklist prompted further objective evaluation based on a 
prespecified diagnostic algorithm (the PML Case Evaluation Algorithm). Cases of new 
neurological symptoms were promptly evaluated by an independent adjudication committee 
(IAC) of academic experts (including a neurologist, a neuroradiologist, and a virologist) using a 
prespecified diagnostic algorithm that included stepwise contrast-enhanced brain magnetic 
resonance imaging and, if indicated, lumbar puncture with polymerase chain reaction analysis of 
cerebrospinal fluid for JC virus DNA. If patients entered the algorithm, study drug was withheld 
until PML could be definitively excluded.  
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Monitoring and Auditing of Study Procedures and Data Quality 
At regular intervals, routine on-site monitoring visits were performed by clinical research 
associates (CRAs) at all sites on the basis of a prespecified written monitoring plan, and 100% of 
data were source verified during these visits. In addition, remote CRA and medical monitoring of 
the study’s electronic database, which included all source documents (case report forms and 
laboratory results), was performed for each patient throughout the study according to the 
monitoring plan. In addition to monitoring visits, clinical quality assurance audits were 
conducted by CRAs.  
An independent data safety monitoring board (DSMB) provided oversight of the phase 3 
vedolizumab program and met at 6-month intervals. The DSMB was composed of 2 
gastroenterologists and a statistician. Before scheduled meetings, the DSMB received unblinded 
tables and listings of all clinical safety data. The DSMB reviewed these data in closed sessions 
and subsequently provided a recommendation to the sponsor. In addition, the DSMB received 
monthly listings of all SAEs that included the most current individual reports of the Council for 
International Organizations of Medical Sciences (CIOMS) form. 
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Patient Eligibility Criteria  
Inclusion Criteria 
1. In the opinion of the investigator, the patient is capable of understanding and complying with 
protocol requirements. 
2. The patient or, when applicable, the patient’s legally acceptable representative signs and dates 
a written, informed consent form and any required privacy authorization prior to the initiation of 
any study procedures. 
3. The patient has a diagnosis of UC established at least 3 months prior to Screening by clinical 
and endoscopic evidence and corroborated by a histopathology report. 
4. The patient is male or female and aged 18 to 85 years, inclusive. 
5. The patient has moderately to severely active UC as determined by a total score on the Mayo 
scale of 6 to 12 with an endoscopic subscore ≥2 within 14 days prior to the randomization. 
6. The patient has evidence of UC proximal to the rectum (≥15 cm of involved colon). 
7. The patient with extensive colitis (up to the hepatic flexure) or pancolitis of >8 years duration 
or left-sided colitis of >12 years duration must have documented evidence that a surveillance 
colonoscopy was performed within 12 months of the initial screening visit (may be performed 
during the Screening Period). 
8. The patient with a family history of colorectal cancer, personal history of increased colorectal 
cancer risk, age >50 years, or other known risk factor must be up-to-date on colorectal cancer 
surveillance (may be performed during Screening). 
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9. The patient: 
a) Has had previous treatment with TNF inhibitor without documented clinical response 
to treatment (e.g., due to lack of response [primary non-responders], loss of response, or 
intolerance [secondary non-responders]), or 
b) Has previously used a TNF inhibitor (except adalimumab), and discontinued its use 
due to reasons other than safety, or 
c) Is naïve to TNF inhibitor but is failing current treatment (e.g., corticosteroids, 5-ASA, 
or immunomodulators). 
10. A male patient who is non-sterilized and sexually active with a female partner of 
childbearing potential agrees to use adequate contraception from signing of informed consent 
throughout the duration of the study and for 5 months after the last dose. 
11. A female patient of childbearing potential who is sexually active with a non-sterilized male 
partner agrees to use routinely adequate contraception from signing of informed consent 
throughout the duration of the study and for 5 months after the last dose. 
 
Exclusion Criteria 
Gastrointestinal Exclusion Criteria 
1. The patient has clinical evidence of abdominal abscess or toxic megacolon at the Screening 
Visit. 
2. The patient has had an extensive colonic resection, subtotal or total colectomy. 
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3. The patient has had ileostomy, colostomy, or known fixed symptomatic stenosis of the 
intestine. 
4. The patient has a diagnosis of Crohn’s colitis or indeterminate colitis, ischemic colitis, 
radiation colitis, diverticular disease associated with colitis, or microscopic colitis. 
5. The patient has received any of the following for the treatment of underlying disease within 30 
days of randomization: 
a) Non-biologic therapies (e.g., cyclosporine, tacrolimus, thalidomide) other than those 
specifically listed in Section Permitted Medications for Treatment of UC. 
b) An approved non-biologic therapy in an investigational protocol. 
6. The patient has received any investigational or approved biologic or biosimilar agent (other 
than those listed in Exclusion Criterion #7) within 60 days or 5 half-lives prior to Screening 
(whichever is longer). 
7. The patient has previously received natalizumab, efalizumab, adalimumab, etrolizumab, 
AMG-181, anti–mucosal addressin cell adhesion molecule-1 antibodies, or rituximab. 
8. The patient has previously received vedolizumab. 
9. The patient currently requires or is anticipated to require surgical intervention for UC during 
the study. 
10. The patient has history or evidence of adenomatous colonic polyps that have not been 
removed, or colonic mucosal dysplasia. 
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Infectious Disease Exclusion Criteria 
11. The patient has evidence of an active infection during the Screening Period. 
12. The patient has evidence of, or treatment for, C. difficile infection or other intestinal 
pathogen within 28 days prior to the first dose of trial drug. 
13. The patient has chronic hepatitis B virus (HBV) infection* or chronic hepatitis C virus 
(HCV) infection. 
* HBV immune patients (i.e., being hepatitis B surface antigen [HBsAg] negative and hepatitis B 
antibody [HBsAb] positive) may, however, be included. 
14. The patient has active or latent TB as evidenced by the following: 
a) A diagnostic TB test performed within 30 days of Screening or during the Screening 
Period that is positive, defined as: 
– Positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests, OR 
– A TB skin test reaction ≥5 mm. 
NOTE: If patients have received BCG vaccine then a QuantiFERON TB Gold test should be 
performed instead of the TB skin test. 
OR 
b) A chest X-ray within 3 months of Day 1 that is suspicious for pulmonary TB, and a 
positive or 2 successive indeterminate QuantiFERON tests (or, a positive T-SPOT TB 
test [Japan only]) within 30 days prior to Screening or during the Screening Period. 
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Note: Patients with documented previously treated TB with a negative QuantiFERON test can be 
included in the study. 
15. The patient has any identified congenital or acquired immunodeficiency (e.g., common 
variable immunodeficiency, human immunodeficiency virus (HIV) infection, organ 
transplantation). 
16. The patient has any live vaccination within 30 days prior to Screening or is planning to 
receive live vaccination during participation in the study. 
17. The patient has a clinically significant infection (e.g., pneumonia, pyelonephritis) within 30 
days prior to Screening, or ongoing chronic infection. 
18. The patient has used a topical (rectal) treatment with (5-ASA) or corticosteroid 
enemas/suppositories within 2 weeks of the administration of the first dose of trial drug. 
General Exclusion Criteria 
19. The patient has a history of hypersensitivity or allergies to vedolizumab or adalimumab. 
20. The patient has any unstable or uncontrolled cardiovascular disorder, heart failure moderate 
to severe (New York Class Association III or IV), any pulmonary, hepatic, renal, GI, 
genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical 
disorder that, in the opinion of the investigator, would confound the study results or compromise 
patient safety. 
21. The patient has history of lupus or lupus-related conditions. 
22. The patient has had a surgical procedure requiring general anesthesia within 30 days prior to 
Screening or is planning to undergo major surgery during the study period. 
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23. The patient has a history of malignancy, except for the following: adequately-treated non-
metastatic basal cell skin cancer; squamous cell skin cancer that has been adequately treated and 
that has not recurred for at least 1 year prior to Screening; and history of cervical carcinoma in 
situ that has been adequately treated and that has not recurred for at least 3 years prior to 
Screening. Patient with remote history of malignancy (e.g., >10 years since completion of 
curative therapy without recurrence) will be considered based on the nature of the malignancy 
and the therapy received and must be discussed with the sponsor on a case-by-case basis prior to 
Screening. 
24. The patient has a history of any major neurological disorders, including stroke, multiple 
sclerosis, brain tumor, demyelinating, or neurodegenerative disease. 
25. The patient has a positive PML subjective symptom checklist at Screening or prior to the 
administration of the first dose of trial drug at Day 1. 
26. The patient has any of the following laboratory abnormalities during the Screening Period: 
 Hemoglobin <8 g/dL. 
 White blood cells (WBC) <3 × 109/L. 
 Lymphocyte <0.5 × 109/L. 
 Platelet count <50 × 109/L or >1200 ×109/L. 
 Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × upper limit of 
normal (ULN). 
 Alkaline phosphatase >3 × ULN. 
 Serum creatinine >2 × ULN. 
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27. The patient has a history of drug abuse (defined as any illicit drug use) or a history of alcohol 
abuse within 1 year prior to the Screening Visit. 
28. The patient has an active psychiatric problem that, in the investigator’s opinion, may 
interfere with compliance with study procedures. 
29. The patient is unable to attend all the study visits or comply with study procedures. 
30. The patient is required to take excluded medications listed in Section 7.3. 
31. If female, the patient is pregnant or lactating or intending to become pregnant before, during, 
or within 5 months after participating in this study; or intending to donate ova during such time 
period. 
32. If male, the patient intends to donate sperm during the course of this study or for 5 months 
thereafter. 
33. The patient is an immediate family member, study site employee, or is in a dependent 
relationship with a study site employee who is involved in conduct of this study (e.g., spouse, 
parent, child, sibling) or may consent under duress. 
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Prespecified Additional Outcomes in Protocol 
 Clinical response (defined as a reduction in total score on the Mayo scale of ≥3 points 
and ≥30% from baseline [or a partial score on the Mayo scale of ≥2 points and ≥25% 
from baseline, if the total score on the Mayo scale was not performed at the visit] with an 
accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding 
subscore of ≤1 point) at Week 52 
 Clinical remission (defined as a total score on the Mayo scale of ≤2 points and no 
individual subscore >1 point) at Week 14 
 Rectal bleeding subscore indicative of mild disease (≤1) at Week 52 
 Physician’s Global Assessment (PGA) subscore indicative of mild disease (≤1) at Week 
52 
 Stool frequency subscore indicative of mild disease (≤1) at Week 52 
 Total score on the Mayo scale of ≤2 points and no individual subscore >1 point where 
rectal bleeding subscore of 0 and endoscopy subscore of 0 at Week 52 
 Endoscopy subscore of 0, rectal bleeding subscore of 0, and stool frequency subscore 
decreases or no change from Baseline at Week 52 
 Endoscopy subscore ≤1, rectal bleeding subscore of 0, and stool frequency subscore of 0 
at Week 52 
 Endoscopy subscore ≤1, rectal bleeding subscore of 0, and stool frequency subscore ≤1 at 
Week 52 
 Endoscopy subscore ≤1, rectal bleeding subscore of 0, stool frequency subscore 
decreases or no change from Baseline, and total score (sum of these 3) ≤1 at Week 52 
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 Inflammatory Bowel Disease Questionnaire (IBDQ) score change of ≥16 points from 
Baseline to Week 52 
 Clinical remission based on IBDQ score >170 at Week 52 
 Change in oral corticosteroid use from Baseline to Week 52 
 Discontinuation of corticosteroids as well as clinical remission at Week 14 among 
patients using corticosteroids at baseline 
 Time to major UC-related events (e.g., hospitalizations, colectomies, and procedures) 
 Change in fecal calprotectin concentrations from Baseline to Weeks 14, 30, and 52 
 Change in histology from Baseline to Week 52 
 Histological remission at Week 14 
 Histological remission at Week 52 
 Observed serum concentration at the end of a dosing interval (Ctrough) of vedolizumab 
 Positive anti-vedolizumab antibodies (AVA) during the study 
 Positive neutralizing AVA 
 Safety for maintenance therapy as assessed by AEs, adverse events of special interest 
(AESIs, including serious infections including opportunistic infection such as PML, liver 
injury, malignancies, infusion-related or injection site reactions or systemic reactions and 
hypersensitivity), serious adverse events (SAEs), vital signs, results of standard 
laboratory tests (clinical chemistry, hematology, coagulation, urinalysis), and results of 
12 lead electrocardiograms (ECGs) 
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Prespecified Exploratory Outcomes in Statistical Analysis Plan 
 Clinical response at Week 14 
 Total score on the Mayo scale of ≤1 and rectal bleeding subscore = 0 at Week 52 
 Durable clinical remission, defined as clinical remission at Week 52 amongst those in 
clinical remission at Week 14 (Note: the denominator will be the patients in the full-
analysis set) 
 Clinical remission at Week 52 and in clinical remission for ≥14 weeks leading up to 
Week 52. Clinical remission is defined by total score on the Mayo scale, or partial score 
on the Mayo scale if the total score on the Mayo scale was not performed at the visit 
(Note the denominator will be the patients in the full-analysis set) 
 Disease control at Week 52, defined as total score on the Mayo scale of ≤2, rectal 
bleeding subscore = 0, endoscopy subscore = 0, C-reactive protein <5 mg/L, fecal 
calprotectin (FCP) <100 ug/g and in histological remission (either by Geboes Score or by 
Robarts Histopathology Index) 
 Rectal bleeding subscore = 0 at Week 52 
 Major UC-related events (e.g., hospitalizations, bowel resection, and procedures) 
throughout the study up to Week 52 
 FCP ≤250 ug/g at Week 14, 30, 52 (among those with FCP >250 ug/g at baseline). (Note 
the denominator will be a subset of patients with FCP >250 ug/g at baseline in the full-
analysis set) 
 Treatment persistence with adalimumab or vedolizumab at Week 68 
 Change from baseline in IBDQ-specific domain at Week 30 and Week 52, including 
bowel symptoms, systemic symptoms, emotional function, and social function 
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 Time to first clinical remission. Clinical remission is defined by total score on the Mayo 
scale, or partial score on the Mayo scale if the total score on the Mayo scale was not 
assessed at the visit 
 Time to first clinical response. Clinical response is defined by total score on the Mayo 
scale, or partial score on the Mayo scale if the total score on the Mayo scale was not 
assessed at the visit 
 Clinical remission by visit (e.g., Week 2, Week 4, Week 6, Week 14, Week 22, Week 30, 
Week 38, Week 46, Week 52). Clinical remission is defined by total score on the Mayo 
scale, or partial score on the Mayo scale if the total score on the Mayo scale was not 
assessed at the visit 
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Statistical Analysis 
The first interim analysis was conducted after approximately 100 patients had been randomized 
into the study for 52 weeks and had completed the Week 52 Final Visit or Early Termination 
Visit. The study design employed a prospectively planned interim analysis using a promising 
zone design with an adaptive sample size re-assessment approach1 (conditional power derived 
from the primary efficacy outcome of clinical remission at Week 52). This was conducted by an 
external independent statistical team. As prespecified in the protocol, the sponsor, investigators, 
and study participants were blinded to this interim analysis and its results. The Independent Data 
Monitoring Committee recommended the predefined maximum total sample size increase of 100 
patients.  
The primary efficacy analysis was performed when all patients had completed Week 52 or 
withdrawn from the study (leaving 7 patients still to complete their Week 68 safety follow-up). 
This was for publication purposes. Final analyses included the off-treatment safety follow-up at 
Week 68.   
1. Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are 
promising: a practical guide with examples. Stat Med. 2011;30:3267-3284. 
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Figure S1. Patient Disposition.  
 
 
AE, adverse event; IV, intravenous; SC, subcutaneous. 
*Includes 2 patients randomized, but never received any study drug. 
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Figure S2. Clinical Remission at Week 52 in Subgroups by Patient Demographic and 
Baseline Characteristics (FAS). 
Plot of treatment differences (dots) and 95% confidence intervals (CIs; horizontal bars) for 
comparing the proportion of patients in clinical remission between vedolizumab and adalimumab 
at Week 52.  
 
CI, confidence interval; FAS, full-analysis set; IV, intravenous; SC, subcutaneous; TNF, tumor 
necrosis factor; UC, ulcerative colitis. 
Clinical remission is defined as a total score on the Mayo scale of ≤2 points (or a partial score on 
the Mayo scale of ≤2 points, if the total score on the Mayo scale was not assessed at the visit) 
and no individual subscore >1 point. 
 
Patients with missing clinical remission status are considered as non-responders. 
The 95% CI for the treatment difference is based on crude estimates using the normal 
approximation method (the Fisher’s exact method used if the numerator is ≤5).  
 
 
29 
 
Figure S3. Clinical Remission and Endoscopic Improvement at Week 52 by Baseline 
Concomitant Medication Use. 
 
CI, confidence interval; eCRF, electronic Case Report Form; IV, intravenous; IWRS, interactive 
Web response system; SC, subcutaneous 
Absence of baseline steroid use reflects data reported by IWRS. Absence of baseline 
immunomodulator use reflects data reported on the eCRF. 
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Figure S4. Clinical Remission at Week 14 in the Overall population and Subgroups by 
Prior TNF Inhibitor Therapy (FAS).   
 
CI, confidence interval; FAS, full-analysis set; IV, intravenous; SC, subcutaneous; TNF, tumor 
necrosis factor.  
Point estimate and 95% CI for the overall analysis were obtained from Cochran-Mantel-Haenszel 
method adjusted by randomization stratification factors: concomitant use of oral corticosteroids 
(Yes/No) and prior use of TNF inhibitor (Yes/No).  
 
Point estimates and the 95% CIs for TNF inhibitor subpopulations were obtained from Cochran-
Mantel-Haenszel method adjusted by randomization stratification factor: concomitant use of oral 
corticosteroids (Yes/No) or the Fisher’s exact method if the numerator is ≤5.  
 
Patients with missing data to determine outcome status were considered as treatment failures; 
i.e., non-responders.  
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Figure S5. Endoscopic Improvement at Week 52 by Patient Demographic and Baseline 
Characteristics (FAS). 
Plot of treatment differences (dots) and 95% confidence intervals (CIs; horizontal bars) for 
comparing the proportions of patients with endoscopic improvement between vedolizumab and 
adalimumab at Week 52.  
 
CI, confidence interval; FAS, full-analysis set; IV, intravenous; SC, subcutaneous; TNF, tumor 
necrosis factor; UC, ulcerative colitis. 
Endoscopic improvement is defined as a Mayo score endoscopic subscore of ≤1 point. 
Patients with missing mucosal healing status are considered as non-responders (i.e., No Mucosal 
Healing). 
 
The 95% CI of the treatment difference is based on crude estimates using the normal 
approximation method (the Fisher’s exact method used if the numerator is ≤5).  
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Figure S6. Corticosteroid-free Clinical Remission at Week 52 by Patient Demographic and 
Baseline Characteristics (FAS). 
Plot of treatment differences (dots) and 95% confidence intervals (CIs; horizontal bars) for 
comparing the proportions of patients with corticosteroid-free clinical remission between 
vedolizumab and adalimumab at Week 52.  
 
CI, confidence interval; FAS, full-analysis set; IV, intravenous; SC, subcutaneous; TNF, tumor 
necrosis factor; UC, ulcerative colitis. 
The 95% CI for the treatment difference is based on crude estimates using the normal 
approximation method (the Fisher’s exact method used if the numerator is ≤5). 
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Figure S7. Oral Corticosteroid Use. 
Mean change in median oral corticosteroid use at Week 52.  
 
eCRF, electronic Case Report Form; IV, intravenous; SC, subcutaneous. 
Only patients with concomitant oral corticosteroid (excludes budesonide) use at Baseline in the 
eCRF are included.  
 
Patients receiving oral corticosteroids at screening who achieved clinical response at the week 6 
and at any subsequent visits underwent a corticosteroid tapering regimen.  
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Figure S8. Histological Remission at Week 52 in Subgroups by Prior TNF Inhibitor Therapy. 
A: Geboes Grading System.  
B: Robarts Histopathology Index.  
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CI, confidence interval; IV, intravenous; SC, subcutaneous; TNF, tumor necrosis factor.  
Shown are the percentages of patients who had histologic remission as indicated by a Geboes 
score lower than 2.0 (on a scale from 0 to 5.4, with higher scores indicating more severe disease 
activity) (Panel A) or by a Robarts Histopathology Index score lower than 3 (on a scale from 0 to 
33, with higher scores indicating more severe disease activity) (Panel B).  
 
Point estimates and the 95% CIs were obtained from Cochran-Mantel-Haenszel (CMH) method 
stratified by randomization stratification factor: concomitant use of oral corticosteroids (Yes/No) 
or the Fisher’s exact method if the numerator is ≤5. 
 
Patients with missing data to determine outcome status were considered as treatment failures; 
i.e., non-responders.  
 
 
36 
 
Figure S9. Histological Remission at Week 14.  
A: Geboes Grading System.  
B: Robarts Histopathology Index.  
 
CI, confidence interval; IV, intravenous; SC, subcutaneous; TNF, tumor necrosis factor.  
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Shown are the percentages of patients who had histologic remission as indicated by a Geboes 
score lower than 2.0 (on a scale from 0 to 5.4, with higher scores indicating more severe disease 
activity) (Panel A) or by a Robarts Histopathology Index score lower than 3 (on a scale from 0 to 
33, with higher scores indicating more severe disease activity) (Panel B).  
 
Point estimate and 95% CI for the overall analysis were obtained from Cochran-Mantel-Haenszel 
method adjusted by randomization stratification factors: concomitant use of oral corticosteroids 
(Yes/No) and prior use of TNF inhibitor (Yes/No).  
 
Point estimates and the 95% CIs for TNF inhibitor subpopulations were obtained from Cochran-
Mantel-Haenszel method adjusted by randomization stratification factor: concomitant use of oral 
corticosteroids (Yes/No) or the Fisher’s exact method if the numerator is ≤5.  
 
Patients with missing data to determine outcome status were considered as treatment failures; 
i.e., non-responders. 
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Figure S10. Minimal Histologic Disease Activity at Week 52. 
A: Geboes Grading System.  
B: Robarts Histopathology Index.  
 
CI, confidence interval; IV, intravenous; SC, subcutaneous. 
 
Shown are the percentages of patients who had minimal histologic disease activity as indicated 
by a Geboes score lower than 3.2 (on a scale from 0 to 5.4, with higher scores indicating more 
severe disease activity) (Panel A) or by a Robarts Histopathology Index score lower than 5 (on a 
scale from 0 to 33, with higher scores indicating more severe disease activity) (Panel B).  
 
Point estimates and the 95% CIs were obtained from Cochran-Mantel-Haenszel (CMH) method 
stratified by randomization stratification factor: concomitant use of oral corticosteroids (Yes/No) 
and prior use of TNF inhibitor (Yes/No).  
 
Patients with missing data to determine outcome status were considered as treatment failures; 
i.e., non-responders. 
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Figure S11. Clinical Response based on Total Score on the Mayo Scale at Week 14 in the 
Overall Population and Subgroups by Prior TNF Inhibitor Therapy.  
 
IV, intravenous; SC, subcutaneous; TNF, tumor necrosis factor. 
Point estimates and the 95% CIs for the overall analysis were obtained from Cochran-Mantel-
Haenszel (CMH) method stratified by randomization stratification factor: concomitant use of 
oral corticosteroids (Yes/No) and prior use of TNF inhibitor (Yes/No).  
 
Point estimates and the 95% CIs for TNF inhibitor subpopulations were obtained from Cochran-
Mantel-Haenszel method adjusted by randomization stratification factor: concomitant use of oral 
corticosteroids (Yes/No) or the Fisher’s exact method if the numerator is ≤5. 
 
Clinical response based on total score on the Mayo scale is defined as a reduction in total score 
on the Mayo scale of ≥3 points and ≥30% from baseline with an accompanying decrease in rectal 
bleeding subscore of ≥1point or absolute rectal bleeding subscore of ≤1 point. Patients with 
missing clinical response status were considered non-responders. 
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Table S1. Schedule of Trial Procedures. 
 Screening Treatment Week Final Visit or 
Early 
Termination 
Visit Week 52 
(b) 
Follow-
up Visit 
Week 
68 (b) 
Study Day/Week: Days -28 to -1 Day 1 (a) 
2 4 6 
8, 
10, 
12 14 
16, 
18, 
20 22 
24, 
26, 
28 30 
32, 
34, 
36 38 
40, 
42, 
44 46 
48, 
50 
Visit Windows 
(Days): 
  ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 
Visit Number:  
1 2 3 4 5 
6-8 
(c) 9 
10-
12 
(c) 13 
14-
16 
(c) 17 
18-
20 
(c) 21 
22-
24 
(c) 25 
26-
27 
(c) 28 29 
Informed consent X                  
Inclusion/exclusion 
criteria X X (a)                 
Demographics and 
medical history X                  
Concurrent medical 
conditions X                  
Medication history X                  
Physical 
examination X X (a) X X X  X  X  X  X  X  X X 
Vital signs (d) X X (a) X X X  X  X  X  X  X  X X 
Weight and height X                  
Flexible 
sigmoidoscopy (e) X      X          X  
Total score on the 
Mayo scale X      X          X  
Partial score on the 
Mayo scale  X X X X    X  X  X  X    
Patient diary X X (a) X X X X X X X X X X X X X X X  
Clinical laboratory 
testing (f) X X (a)   X  X    X    X  X X 
Urinalysis X                X  
ADA testing (g)  X (a)   X  X  X  X  X    X X 
PK testing (g)  X (a)   X  X  X  X  X    X X 
HIV/Hepatitis panel X                  
Tuberculosis 
screening (h) X        
X 
(h)        X (h)  
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Pharmacogenomic 
DNA and RNA 
sample collection 
 X (a)                
 
 
 
Serum pregnancy 
test (i) X                  
Urine pregnancy test 
(i)  X (a) X X X 
X 
(i) X 
X 
(i) X 
X 
(i) X 
X 
(i) X 
X 
(i) X 
X 
(i) X X 
IBDQ  X (a)         X      X  
ECG X                X  
Stool sample for C. 
difficile X                  
Stool sample for 
calprotectin  X     X    X      X  
PML checklist X X (a) X  X  X  X  X  X  X  X X 
PML wallet card X                X  
SC dosing 
(adalimumab or 
placebo) 
 X X X X X X X X X X X X X X X   
IV dosing 
(vedolizumab or 
placebo) 
 X X  X  X  X  X  X  X    
PTE assessment (j) X X                 
Adverse events (k)  X X X X X X X X X X X X X X X X X 
Concomitant 
medications and 
procedures (l) 
 X X X X X X X X X X X X X X X X X 
ADA, antidrug antibody; AE, adverse event; ECG, electrocardiogram; HIV, human immunodeficiency virus; IBDQ, Inflammatory Bowel Disease Questionnaire; IV, intravenous; PK, pharmacokinetics; 
PML, progressive multifocal leukoencephalopathy; PTE, pretreatment event; SC, subcutaneous; TB, tuberculosis. 
(a) Assessments to be completed predose. 
(b) Patients discontinued from the study for any reason will complete the Early Termination Visit and the Follow-up Visit Week 68. 
(c) Non-clinic visits. Patient will self-inject at home. On other visits SC dosing will be performed by site staff or patient under supervision of site staff. 
(d) Vital signs will include body temperature, respiratory rate, blood pressure, and pulse (bpm). On dosing days, vital signs are taken predose. 
(e) Biopsies to be collected at Screening and Weeks 14 and 52. For patients without cancer surveillance endoscopy performed in last 12 months, the investigator can perform a colonoscopy at Screening. 
Evaluation of endoscopy results will be performed by the central reader. 
(f) Blood sample obtained during Screening should be in fasted state. 
(g) Blood samples for the ADA (against vedolizumab or adalimumab) assessments will be collected from all patients at Day 1 and Weeks 6, 14, 22, 30, 38, 52, and 68. On dosing days, blood samples must be 
taken predose. An aliquot of this sample will be used to determine the serum concentration of vedolizumab. 
(h) Assessed by QuantiFERON test or TB skin test reaction. For sites in Taiwan, QuantiFERON test will also need to be performed at Week 22 and Week 52/Early Termination visit. 
(i) Women of childbearing potential only. Urine pregnancy test should be done before every IV infusion and at Weeks 10, 18, 26, 34, 42, and 50. 
(j) PTEs will be captured immediately following the signing of the informed consent at the Screening Visit, up until the first dose of trial drug. Collection of AEs will begin following first dose of trial drug 
and will continue through Week 68/Final Safety Visit. 
(k) Collection of all SAEs will begin once the informed consent is signed and will continue through Week 68/Final Safety Visit. 
(l) Monitoring of concomitant medications and procedures will begin at signing of the informed consent. 
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Table S2. Baseline Disease Characteristics. 
Characteristic 
Adalimumab 
(N = 386) 
Vedolizumab 
(N = 385) 
Total score on the Mayo scale — no. (%)* 
Mild (score <6)† 5 (1.3) 9 (2.3) 
Moderate (score = 6 to 8)‡ 169 (43.8) 154 (40.0) 
Severe (score = 9 to 12)‡ 210 (54.4) 217 (56.4) 
Partial score on the Mayo scale (mean ± 
SD)¶  
6.0±1.3 6.1±1.5 
*Mayo scores range from 0 to 12, with higher scores indicating more active disease; sub-
components: stool frequency, rectal bleeding, endoscopy (sigmoidoscopy), physician global 
assessment. Scores were available for 384 patients in the adalimumab group and 380 patients in 
the vedolizumab group. 
†Patients with mild disease represented significant protocol deviations. 
‡In total, 98.2% of patients in adalimumab group and 96.4% of patients in the vedolizumab 
group had moderately to severely active ulcerative colitis. 
¶The partial score on the Mayo scale consists of the total score on the Mayo scale minus the 
sigmoidoscopy subscore; range, 0 to 9, with higher scores indicating more active disease. Scores 
were available for 384 patients in the adalimumab group and 381 patients in the vedolizumab 
group. 
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Table S3. Post Hoc Analysis of Clinical Remission and Endoscopic Improvement at Week 
52, Using the Weighted Cochran–Mantel–Haenszel Method. 
Week 52 Outcomes 
Stage 1 
(N = 93) 
Stage 2 
(N = 676) 
CHW Method 
(N = 769) 
Adalimumab, 
n (%) 
(N = 45) 
Vedolizumab, 
n (%) 
(N = 48) 
Adalimumab, 
n (%) 
(N = 341) 
Vedolizumab, 
n (%) 
(N = 335) 
Adjusted 
P value 
Clinical remission 11 (24.4) 14 (29.2) 76 (22.3) 106 (31.6) 0.0062 
Endoscopic 
improvement 
13 (28.9) 18 (37.5) 94 (27.6) 134 (40.0) 0.0005 
The P values from the Cochran–Mantel–Haenszel (CHW) method were obtained from a weighted combination of test 
statistics from Stage 1 (Interim Analysis 1 data) and Stage 2 (post Interim Analysis 1 data) weighted by actual interim 
sample size and planned total sample size. 
The results were consistent with the planned efficacy analysis using the Cochran–Mantel–Haenszel method. 
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Table S4. Sensitivity Analysis to Assess the Impact of Dropouts Under Different Missing 
Data Mechanisms for Primary and Secondary Outcomes. 
Week 52 Outcomes 
Adalimumab SC 
40 mg Q2Wa 
Vedolizumab IV 
300 mg Q8Wa 
Treatment 
Differenceb 
(95% CI) P value 
Clinical remission, % (95% 
CI)c 
(N = 386) 
25.9 (21.3, 30.4) 
(N = 383) 
37.2 (32.2, 42.2) 
11.3 (4.6, 18.0) 0.002 
Endoscopic improvement, 
% (95% CI)c 
(N = 386) 
33.6 (28.5, 38.7) 
(N = 383) 
46.8 (41.5, 52.1) 
13.2 (6.0, 20.3) <0.001 
Corticosteroid-free 
remission, % (95% CI)c 
(N = 119) 
24.7 (16.6, 32.7) 
(N = 111) 
16.9 (9.3, 24.4) 
–7.8 (–18.8, 3.1) NS 
CI, confidence interval; Q2W, once every two weeks; Q8W, once every 8 weeks; NS, not significant. 
aThe 95% CI for the proportions was based on the Clopper-Pearson method. 
bThe treatment difference in proportions and the corresponding 95% CI and P value were based on the Cochran-
Mantel-Haenszel method, stratified by concomitant use of oral corticosteroids (Yes/No) and prior use of a TNF 
inhibitor (Yes/No). The proportions, treatment difference, and P value were combined using Rubin’s rules from 50 
imputed datasets using PROC MIANALYZE. The Wilson-Hilferty transformation was applied to test statistics 
before PROC MIANALYZE. 
cSensitivity Analysis: The impact of dropouts was explored by using a hybrid imputation approach where patients 
with missing efficacy data by discontinuation due to an adverse event or lack of efficacy were imputed as non-
responder (under Missing Not At Random assumption) and missing efficacy data due to other reasons were 
imputed using multiple imputation (under Missing At Random assumption). For the multiple imputation, each 
component of the total score on the Mayo scale was imputed by treatment group via a multivariate step-wise 
approach using fully conditional specification (FCS ordinal logistic) methods,1 respectively. Missing baseline total 
score on the Mayo scale, if any, was imputed using the relevant demographic and baseline disease characteristic 
data (namely, age, duration of UC, baseline disease severity). Subsequent visits were imputed using all the previous 
visits in a stepwise fashion. Fifty imputation datasets were computed for each component of total score on the 
Mayo scale. The total and/or partial scores on the Mayo scale were derived subsequently. The efficacy outcome 
status was then determined from the total score on the Mayo scale derived using the observed and the imputed 
Mayo subscores. 
1. Ratitch B, Lipkovich I, O’Kelly M. Combining analysis results from multiply imputed categorical data. Paper 
presented at: PharmaSUG 2013; May 12-15, 2013; Chicago, IL. Abstract SP03. Available at: 
https://pharmasug.org/proceedings/2013/SP/PharmaSUG-2013-SP03.pdf   
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Table S5. Results from Prespecified Analyses of Efficacy Outcomes. 
Outcomea 
Adalimumab SC 
40 mg Q2W 
(N=386) 
Vedolizumab IV 
300 mg Q8W 
(N=383) 
Treatment Difference, 
(95% CI)p 
Clinical remissionb at Week 52, n % 87 (22.5) 120 (31.3) 8.8 (2.5, 15.0) 
Endoscopic improvement (mucosal healing)c at Week 52, n 
(%) 
107 (27.7) 152 (39.7) 11.9 (5.3, 18.5) 
CS-free clinical remissiond at Week 52, n (%) 26 (21.8) 14 (12.6) -9.3 (-18.9, 0.4) 
Clinical responsee at Week 52, n (%) 166 (43.0) 211 (55.1) 12.0 (5.1, 19.0) 
Clinical remissionb at Week 14, n (%) 82 (21.2) 102 (26.6) 5.3 (-0.7, 11.4) 
Rectal bleeding subscore indicative of mild disease (≤1) at 
Week 52, n (%) 
211 (54.7) 252 (65.8) 11.1 (4.2, 17.9) 
Physician’s Global Assessment (PGA) subscore indicative of 
mild disease (≤1) at Week 52, n (%) 
189 (49.0) 234 (61.1) 12.1 (5.1, 19.0) 
Stool frequency subscore indicative of mild disease (≤1) at 
Week 52, n (%) 
173 (44.8) 223 (58.2) 13.3 (6.4, 20.3) 
Clinical remissionb where rectal bleeding subscore of 0 and 
endoscopy subscore of 0 at Week 52, n (%) 
54 (14.0) 85 (22.2) 8.2 (2.8, 13.5) 
Endoscopy subscore of 0, rectal bleeding subscore of 0, and 
stool frequency subscore decreases or no change from 
Baseline at Week 52, n (%) 
55 (14.2) 89 (23.2) 8.9 (3.5, 14.4) 
Endoscopy subscore ≤1, rectal bleeding subscore of 0, and 
stool frequency subscore of 0 at Week 52, n (%) 
75 (19.4) 91 (23.8) 4.3 (-1.5, 10.1) 
Endoscopy subscore ≤1, rectal bleeding subscore of 0, and 
stool frequency subscore ≤1 at Week 52, n (%) 
91 (23.6) 127 (33.2) 9.5 (3.2, 15.9) 
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Table S5. Results from Prespecified Analyses of Efficacy Outcomes. 
Outcomea 
Adalimumab SC 
40 mg Q2W 
(N=386) 
Vedolizumab IV 
300 mg Q8W 
(N=383) 
Treatment Difference, 
(95% CI)p 
Endoscopy subscore ≤1, rectal bleeding subscore of 0, stool 
frequency subscore decreases or no change from Baseline, 
and total score (sum of these 3) ≤1 at Week 52, n (%) 
79 (20.5) 112 (29.2) 8.7 (2.7, 14.8) 
IBDQ score change of ≥16 points from Baseline to Week 52, 
n (%) 
163 (42.2) 199 (52.0) 9.7 (2.7, 16.7) 
Clinical remission based on IBDQ score >170 at Week 52, n 
(%) 
156 (40.4) 192 (50.1) 9.6 (2.8, 16.5) 
*Change in oral corticosteroid use from Baseline to Week 
52, mean (SD): 
 
 
 
 
 
 
 Cumulative CS exposure (in mg of prednisone 
equivalent)f  
3321.8 (3373.9) 3764.9 (3647.5) – 
 Duration of CS use (days)g 194.6 (138.4) 219.1 (167.0) – 
 Change in median oral CS dose from baseline up to 
Week 52 (in mg of prednisone equivalent) 
–8.55 (10.77) –11.62 (11.12) – 
CS-free clinical remissionc at Week 14, n (%) 8 (6.7) 7 (6.3) -0.5 (-6.8, 5.9) 
Major UC-related events,h Hazard ratio, 95% CI:i 
 UC-related hospitalizations, n (%) 
 UC-related bowel resections, n (%) 
 UC-related procedures, n (%) 
 
20 (5.2) 
3 (0.8) 
8 (2.1) 
 
15 (3.9) 
0 
7 (1.8) 
0.061 (0.035, 0.105) 
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Table S5. Results from Prespecified Analyses of Efficacy Outcomes. 
Outcomea 
Adalimumab SC 
40 mg Q2W 
(N=386) 
Vedolizumab IV 
300 mg Q8W 
(N=383) 
Treatment Difference, 
(95% CI)p 
*Change in fecal calprotectin concentrations (µg/g), mean 
(SD) LOCF: 
 Baseline to Week 14 
 Baseline to Week 30 
 Baseline to Week 52 
 
 
–1004.4 (4579.12) 
–1043.3 (4575.62) 
–1160.3 (4508.21) 
 
 
–1393.2 (6052.67) 
–1601.5 (6463.41) 
–1631.5 (6424.48) 
 
 
–409.9 (-824.9, 5.1) 
–399.4 (-838.2, 39.5) 
–315.7 (–764.2, 132.8) 
Change in histology from Baseline to Week 52 per Geboes 
(≥ 3 at baseline), n 
 Improving (change ≤1) 
 No change (-1< change <1) 
 Worsening (change ≥1) 
 Missing 
 
 
150 
12 
41 
146 
 
 
225 
4 
29 
104 
 
 
– 
– 
– 
– 
Histological remission, per Geboes, n (%) 
 Week 14 
 Week 52 
 
12 (3.1) 
12 (3.1) 
 
19 (5.0) 
40 (10.4) 
 
1.8 (-0.9, 4.6) 
7.3 (3.8, 10.8) 
Histological remission, per RHI, n (%) 
 Week 14 
 Week 52 
 
62 (16.1) 
77 (19.9) 
 
98 (25.6) 
144 (37.6) 
 
9.5 (3.8, 15.2) 
17.6 (11.3, 23.8) 
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Table S5. Results from Prespecified Analyses of Efficacy Outcomes. 
Outcomea 
Adalimumab SC 
40 mg Q2W 
(N=386) 
Vedolizumab IV 
300 mg Q8W 
(N=383) 
Treatment Difference, 
(95% CI)p 
Exploratory Efficacy Outcomes Defined in the Statistical Analysis Plan but not in the Protocol:   
Clinical responsee at Week 14, n (%) 177 (45.9) 257 (67.1) 21.2 (14.4, 28.0) 
Total score on the Mayo scale ≤1 and rectal bleeding 
subscore = 0 at Week 52, n (%) 
70 (18.1) 101 (26.4) 8.2 (2.4, 14.0) 
Durable clinical remission at Week 52j , n (%) 46 (11.9) 70 (18.3) 6.3 (1.3, 11.3) 
Clinical remissionk at Week 52 and clinical remission for 
≥14 weeks leading up to Week 52, n (%) 
74 (19.2) 105 (27.4) 8.2 (2.3, 14.2) 
Disease controll at Week 52, n (%) 23 (6.0) 41 (10.7) 4.7 (0.8, 8.6) 
Rectal bleeding subscore = 0 at Week 52, n (%) 170 (44.0) 214 (55.9) 11.8 (4.8, 18.8) 
Major UC-related events (eg, hospitalizations, bowel 
resection, and procedures) throughout the trial up to Week 
52, n (%) 
25 (6.5) 17 (4.4) -2.0 (-5.2, 1.2) 
FCP ≤250 µg/g at Week 14, 30, 52 (among those in the FAS 
with FCP >250 µg/g at baseline), n (%) 
 Week 14 
 Week 30 
 Week 52 
 
 
80 (26.8) 
73 (24.5) 
86 (28.9) 
 
 
97 (31.9) 
103 (33.9) 
107 (35.2) 
 
 
5.3 (-1.9, 12.6) 
9.6 (2.4, 16.9) 
6.6 (-0.7, 14.0) 
Still on adalimumab or vedolizumab at Week 68, n (%) 21 (5.4) 15 (3.9) -1.5 (-4.5, 1.5) 
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Table S5. Results from Prespecified Analyses of Efficacy Outcomes. 
Outcomea 
Adalimumab SC 
40 mg Q2W 
(N=386) 
Vedolizumab IV 
300 mg Q8W 
(N=383) 
Treatment Difference, 
(95% CI)p 
*Change from baseline in IBDQ-specific bowel symptoms 
domain, mean (SD) LOCF: 
 Week 30 
 Week 52  
 
 
13.8 (14.61) 
13.9 (15.77) 
 
 
17.3 (14.51) 
17.4 (15.74) 
 
 
3.1 (1.1, 5.2) 
3.0 (0.8, 5.2) 
*Time to first clinical remission (day)k, median 154 100 – 
*Time to first clinical response (day)m, median 28 29 – 
Clinical remissionk by visit, n (%):  
 Week 2 
 Week 4 
 Week 6 
 Week 14 
 Week 22 
 Week 30 
 Week 38 
 Week 46 
 Week 52 
 
66 (17.1) 
109 (28.2) 
124 (32.1) 
140 (36.3) 
162 (42.0) 
162 (42.0) 
152 (39.4) 
154 (39.9) 
143 (37.0) 
 
52 (13.6) 
109 (28.5) 
154 (40.2) 
194 (50.7) 
213 (55.6) 
202 (52.7) 
212 (55.4) 
206 (53.8) 
191 (49.9) 
 
– 
– 
– 
– 
– 
– 
– 
– 
– 
 
 
50 
 
Table S5. Results from Prespecified Analyses of Efficacy Outcomes. 
Outcomea 
Adalimumab SC 
40 mg Q2W 
(N=386) 
Vedolizumab IV 
300 mg Q8W 
(N=383) 
Treatment Difference, 
(95% CI)p 
Clinical responsem by visit, n (%) 
 Week 2 
 Week 4 
 Week 6 
 Week 14 
 Week 22 
 Week 30 
 Week 38 
 Week 46 
 Week 52 
 
176 (45.6) 
217 (56.2) 
232 (60.1) 
229 (59.3) 
229 (59.3) 
222 (57.5) 
206 (53.4) 
200 (51.8) 
193 (50.0) 
 
161 (42.0) 
233 (60.8) 
263 (68.7) 
276 (72.1) 
278 (72.6) 
262 (68.4) 
263 (68.7) 
251 (65.5) 
233 (60.8) 
 
– 
– 
– 
– 
– 
– 
– 
– 
– 
Minimum histologic disease activity per Geboesn, n (%) 
 Week 14 
 Week 52 
 
49 (12.7) 
53 (13.7) 
 
81 (21.1) 
128 (33.4) 
 
8.4 (3.2, 13.6) 
19.6 (13.8, 25.5) 
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Table S5. Results from Prespecified Analyses of Efficacy Outcomes. 
Outcomea 
Adalimumab SC 
40 mg Q2W 
(N=386) 
Vedolizumab IV 
300 mg Q8W 
(N=383) 
Treatment Difference, 
(95% CI)p 
Minimal histologic disease activity per RHIo, n (%) 
 Week 14 
 Week 52 
 
94 (24.4) 
99 (25.6) 
 
143 (37.3) 
162 (42.3) 
 
12.9 (6.5, 19.4) 
16.6 (10.0, 23.1) 
AVA, anti-vedolizumab antibodies; Ctrough, trough concentration; CS, corticosteroid; FAS, full-analysis set; FCP, fecal calprotectin; IBDQ, Inflammatory 
Bowel Disease Questionnaire; LOCF, Last Observation Carried Forward; RHI, Robarts Index; UC, ulcerative colitis 
aOutcomes indicate proportion of patients unless preceded by an asterisk (*). 
bClinical remission: total score on the Mayo scale of ≤2 points and no individual subscore >1 point. 
cEndoscopic improvement: Mayo endoscopic subscore ≤1 point. 
dCS-free clinical remission: The proportion of patients using oral CSs at Baseline who have discontinued CSs and are in clinical remission. Only patients 
with reported baseline oral corticosteroid use were included in the analysis. 
eClinical response: Reduction in total score on the Mayo scale of ≥3 points and ≥30% from baseline [or a partial score on the Mayo scale of ≥2 points and 
≥25% from baseline, if the total score on the Mayo scale was not performed at the visit] with an accompanying decrease in rectal bleeding subscore of ≥1 
point or absolute rectal bleeding subscore of ≤1 point). 
fCumulative CS exposure: Total amount of CSs taken by a patient throughout the trial. 
gDuration of CS use: The number of days from baseline to the date of discontinuation of corticosteroid in those patients who were on corticosteroid at 
baseline. 
hPatients who do not have a major UC-related event were censored at the date of last contact or assessment. Some UC-related events may have been 
counted more than once in this Table. UC-related events occurring beyond 12 months were in the safety follow-up period. 
iThe hazard ratio comparing vedolizumab to adalimumab was obtained using a Wei-Lin-Weissfeld (WLW) Cox regression model for multiple events with 
treatment group, baseline total score on the Mayo scale, randomization stratification factors and geographic region as independent variables. 
jDurable clinical remission: Clinical remission at Week 52 amongst those in clinical remission at Week 14. The denominator is the patients in the full-
analysis set. 
kClinical remission defined by partial score on the Mayo scale.  
lTotal score on the Mayo scale of ≤2 rectal bleeding subscore = 0, endoscopy subscore = 0, CRP <5 mg/L, FCP <100 µg/g and in histological remission 
(either by Geboes or by RHI). 
mClinical response is defined by partial score on the Mayo scale. 
nMinimum histological disease activity per Geboes: Geboes score <3.2. 
oMinimum histological disease activity per RHI: RHI <5. 
pThe treatment difference in proportions and associated 95% CI for proportions were based on the Cochran-Mantel-Haenszel method, stratified by 
concomitant use of oral corticosteroids (Yes/No) and prior TNF inhibitor use (Yes/No), the Fisher’s exact method was used if the numerator was ≤5. 
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Table S6. Most Frequent Adverse Events. 
Event 
Adalimumab 
(N = 386)* 
Vedolizumab 
(N = 383)* 
Patients, n (%) 
≥ 1 AE 138 (35.8) 126 (32.9) 
Colitis ulcerative 63 (16.3) 44 (11.5) 
Nasopharyngitis 30 (7.8) 27 (7.0) 
Headache 21 (5.4) 27 (7.0) 
Anemia 26 (6.7) 20 (5.2) 
Abdominal pain 20 (5.2) 18 (4.7) 
Upper respiratory tract infection 17 (4.4) 20 (5.2) 
*Adverse events were classified according to the Medical Dictionary for Regulatory Activities 
System Organ Class categorization and preferred terms (version 21.0).  
The safety population was defined as all patients who received at least one dose of a trial drug. 
Patients with one or more adverse events within a level of MedDRA term are counted only 
once in that level. 
AEs that start or worsen after the first dose of a trial drug and up to 126 days after the last dose 
of a trial drug. 
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Table S7. Serious Adverse Events. 
Event 
Adalimumab 
(N = 386)* 
Vedolizumab 
(N = 383)* 
Patients, n (%) 
Any serious AEs 53 (13.7) 42 (11.0) 
Anemia 4 (1.0) 1 (0.3) 
Angina pectoris 0 1 (0.3) 
Myocardial ischemia 1 (0.3) 0 
Pericarditis  0 1 (0.3) 
Blindness 0 1 (0.3) 
Large intestine polyp 1 (0.3) 0 
Colitis ulcerative 25 (6.5) 19 (5.0) 
Colitis 1 (0.3) 0 
Inflammatory bowel disease 1 (0.3) 0 
Diarrhea 0 2 (0.5) 
Small intestinal obstruction 0 1 (0.3) 
Abdominal pain 1 (0.3) 3 (0.8) 
Ileus 0 1 (0.3) 
Inguinal hernia 1 (0.3) 1 (0.3) 
Peritoneal hemorrhage 1 (0.3) 0 
Proctitis 0 1 (0.3) 
Incarcerated umbilical hernia 1 (0.3) 0 
Umbilical hernia 1 (0.3) 0 
Therapeutic response decreased 1 (0.3) 0 
Drug hypersensitivity 1 (0.3) 0 
Appendicitis 1 (0.3) 1 (0.3) 
Anal abscess 1 (0.3) 0 
Clostridium difficile colitis 0 1 (0.3) 
Clostridium difficile infection 0 1 (0.3) 
Cytomegalovirus infection 1 (0.3) 3 (0.8) 
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Table S7. Serious Adverse Events. 
Event 
Adalimumab 
(N = 386)* 
Vedolizumab 
(N = 383)* 
Patients, n (%) 
Liver abscess 1 (0.3) 0 
Varicella 1 (0.3) 0 
Wound infection 1 (0.3) 0 
Pneumonia 2 (0.5) 0 
Gastroenteritis viral 0 1 (0.3) 
Traumatic hemothorax 1 (0.3) 0 
Ankle fracture 1 (0.3) 0 
Stab wound 1 (0.3) 0 
Post procedural complication 0 1 (0.3) 
Thoracic vertebral fracture 0 1 (0.3) 
Gamma-glutamyltransferase increased 1 (0.3) 1 (0.3) 
Alanine aminotransferase increased 0 1 (0.3) 
Aspartate aminotransferase increased 0 1 (0.3) 
Blood alkaline phosphatase increased 1 (0.3) 0 
Hyponatremia 1 (0.3) 0 
Intervertebral disc protrusion 0 2 (0.5) 
Muscular weakness 1 (0.3) 0 
Pain in extremity 1 (0.3) 0 
Adenocarcinoma of colon 0 1 (0.3) 
Brain stem hemorrhage 1 (0.3) 0 
Cerebrovascular accident 1 (0.3) 0 
Dysgraphia 0 1 (0.3) 
Seizure 0 1 (0.3) 
Nerve root compression 0 2 (0.5) 
Major depression 0 1 (0.3) 
Acute kidney injury 1 (0.3) 0 
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Table S7. Serious Adverse Events. 
Event 
Adalimumab 
(N = 386)* 
Vedolizumab 
(N = 383)* 
Patients, n (%) 
Ureterolithiasis 0 1 (0.3) 
Dyspnea 1 (0.3) 0 
Pneumothorax spontaneous 0 1 (0.3) 
Dermatitis 0 1 (0.3) 
Psoriasis 1 (0.3) 0 
Hypovolemic shock 1 (0.3) 0 
Thrombophlebitis superficial 1 (0.3) 1 (0.3) 
*Adverse events were classified according to the Medical Dictionary for Regulatory Activities 
System Organ Class categorization and preferred terms (version 21.0).  
The safety population was defined as all patients who received at least one dose of a trial drug. 
Patients with one or more adverse events within a level of MedDRA term are counted only 
once in that level. 
AEs that start or worsen on or after the first dose of a trial drug and up to 126 days after the 
last dose. 
 
